ADAM12 as a marker of trisomy 18 in the first and second trimester of pregnancy

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 20, Issue 9, 2007, Pages 645-650

  Spencer, Kevin ^a,b,c   Cowans, Nicholas J ^a  

^a HAROLD WOOD HOSPITAL   (United Kingdom)

^b KING'S COLLEGE LONDON   (United Kingdom)

^c KING GEORGE HOSPITAL   (United Kingdom)

Author keywords

Aneuploidy; Free hCG; Growth factors; Integrins; PAPP A; Prenatal screening

Indexed keywords

ADAM PROTEIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; PREGNANCY ASSOCIATED PLASMA PROTEIN A; PROTEIN ADAM 12; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; FALSE POSITIVE RESULT; FEMALE; FIRST TRIMESTER PREGNANCY; FLUOROMETRY; GENETIC MARKER; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; NUCHAL TRANSLUCENCY MEASUREMENT; POPULATION DISTRIBUTION; PRENATAL SCREENING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REGRESSION ANALYSIS; SECOND TRIMESTER PREGNANCY; TRISOMY 18;

ADAM PROTEINS; BIOLOGICAL MARKERS; CHROMOSOMES, HUMAN, PAIR 18; FEMALE; HUMANS; MEMBRANE PROTEINS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; TRISOMY;

EID: 34547869797     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.1080/14767050701483389     Document Type: Article

References (38)

1. Snijders RJ, Sebire NJ, Nicolaides KH. Maternal age and gestational age-specific risks for chromosome defects. Fetal Diagn Ther 1995;10:356-367.
2. Sherod C, Sebire NJ, Soares W, Snijders RJM, Nicolaides KH. Prenatal diagnosis of trisomy 18 at the 10-14 week ultrasound scan. Ultrasound Obstet Gynecol 1997;10:387-390.
3. Snijders RJ, Brizot ML, Faria M, Nicolaides KH. Fetal exomphalos at 11 to 14 weeks of gestation. J Ultrasound Med 1995;14:569-574.
4. Spencer K, Macri JN, Aitken DA, Connor JM. Free β-hCG as first trimester marker for fetal trisomy. Lancet 1992;339:1480.
5. Brambati B, Lanzani A, Tului L. Ultrasound and biochemical assessment of first trimester pregnancy. In: Chapman M, Grudzinskas JG, Chard T, editors. The embryo: Normal and abnormal development and growth. New York: Springer-Verlag; 1991. pp 181-194.
6. Tul N, Spencer K, Noble P, Chan C, Nicolaides K. Screening for trisomy 18 by fetal nuchal translucency and maternal serum free β-hCG and PAPP-A at 10-14 weeks of gestation. Prenat Diagn 1999;19:1035-1042.
7. Nicolaides KH, Spencer K, Avgidou K, Faiola S, Falcon O. Multicenter study of first trimester screening for trisomy 21 in 75,821 pregnancies: Results and estimation of the potential impact of individual risk-orientated two-stage first trimester screening. Ultrasound Obstet Gynecol 2005;25:221-226.
8. Spencer K, Nicolaides KH. A first trimester trisomy13/trisomy18 risk algorithm combining fetal nuchal translucency thickness, maternal serum free β-hCG and PAPP-A. Prenat Diagn 2002;22:877-879.
9. Papageorghiou AT, Avgidou K, Spencer K, Nix B, Nicolaides KH. Sonographic screening for trisomy 13 at 11 to 13+6 weeks of gestation. Am J Obstet Gynecol 2006;194:397-401.
10. Liao AW, Snijders R, Geerts L, Spencer K, Nicolaides KH. Fetal heart rate in chromosomally abnormal fetuses. Ultrasound Obstet Gynecol 2000;16:610-613.
11. Gilpin BJ, Loechel F, Mattei MG, Engvall E, Albrechtsen R, Wewer UM. A novel, secreted form of human ADAM 12 (meltrin alpha) provokes myogenesis in vivo. J Biol Chem 1998;273:157-166.
12. Shi Z, Xu W, Loechel F, Wewer UM, Murphy LJ. ADAM 12, a disintegrin metalloprotease, interacts with insulin-like growth factor-binding protein-3. J Biol Chem 2000;275:18574-18580.
13. Loechel F, Fox JW, Murphy G, Albrechtsen R, Wewer UM. ADAM 12 cleaves IGFBP-3 and IGFBP-5 and is inhibited by TIMP-3. Biochem Biophys Res Commun 2000;278:511-515.
14. Rosenfeld RG, Roberts CT. The IGF system. Molecular biology, physiology, and clinical applications. Totowa, New Jersey, USA, Humana Press; 1999. pp 1-787.
15. Laigaard J, Sorensen T, Frohlich C, Pedersen BN, Christiansen M, Schiott K, Uldbjerg N, Albrechtsen R, Clausen HV, Ottesen B, Wewer UM. ADAM12: A novel first-trimester maternal serum marker for Down syndrome. Prenat Diagn 2003;23:1086-1091.
16. Laigaard J, Cuckle H, Wewer UM, Christiansen M. Maternal serum ADAM12 levels in Down's and Edwards' syndrome pregnancies at 9-12 weeks gestation. Prenat Diagn 2006;26:689-691.
17. Laigaard J, Christiansen M, Frohlich C, Pedersen BN, Ottesen B, Wewer UM. The level of ADAM12 in maternal serum is an early first-trimester marker of fetal trisomy 18. Prenat Diagn 2005;25:45-46.
18. Laigaard J, Sorensen T, Placing S, Holck P, Frohlich C, Wojdemann KR, Sundberg K, Shalmi AC, Tabor A, Norgaard-Pedersen B, et al. Reduction of the disintegrin and metalloprotease ADAM12 in preeclampsia. Obstet Gynecol 2005;106:144-149.
19. Laigaard J, Spencer K, Christiansen M, Cowans NJ, Larsen SO, Pedersen BN, Wewer UM. ADAM 12 as a first trimester maternal serum marker in screening for Down syndrome. Prenat Diagn 2006;26:973-979.
20. Christiansen M, Spencer K, Laigaard J, Cowans NJ, Larsen SO, Wewer UM. ADAM12 as a second trimester maternal serum marker in screening for Down's syndrome. Prenat Diagn 2007;27:611-615.
21. Spencer K, Spencer CE, Power M, Dawson C, Nicolaides KH. Screening for chromosomal abnormalities in the first trimester using ultrasound and maternal serum biochemistry in a one-stop clinic: A review of three years prospective experience. BJOG 2003;110:281-286.
22. Spencer K. Second trimester prenatal screening for Down's syndrome using alpha-fetoprotein and free beta hCG: A seven year review. BJOG 1999;106:1287-1293.
23. Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10-14 weeks using fetal nuchal translucency, maternal serum free β-human chorionic gonadotropin and pregnancy associated plasma protein-A. Ultrasound Obstet Gynaecol 1999;13:231-237.
24. Snijders RJ, Noble P, Sebire N, Souka A, Nicolaides KH. UK multicentre project on assessment of risk for trisomy 21 by maternal age and fetal nuchal translucency thickness at 10-14 weeks of gestation. Lancet 1998;18:519-521.
25. Snijders RJ, Sundberg K, Holzgreve W, Henry G, Nicolaides KH. Maternal age and gestation specific risk for trisomy 21. Ultrasound Obstet Gynaecol 1999;13:167-170.
26. Ong CY, Liao AW, Spencer K, Munim S, Nicolaides KH. First trimester maternal serum free β human chorionic gonadotrophin and pregnancy associated plasma protein A as predictors of pregnancy complications. BJOG 2000;107:1265-1270.
27. Spencer K, Bindra R, Nicolaides KH. Maternal weight correction of maternal serum PAPP-A and free β-hCG when screening for trisomy 21 in the first trimester of pregnancy. Prenat Diagn 2003;23:851-855.
28. Nicolaides KH, Snijders RJ, Cuckle HS. Correct estimation of parameters for ultrasound nuchal translucency screening. Prenat Diagn 1998;18:519-521.
29. Royston P, Thompson SG. Model based screening by risk with application to Down's syndrome. Stats Med 1992;11:257-268.
30. Office of National Statistics. Series FM1 No. 33. Birth statistics (2004). Stationery Office: London; 2005.
31. Spencer K, Crossley JA, Aitken DA, Nix ABJ, Dunstan FDJ, Williams K. Temporal changes in maternal serum biochemical markers of trisomy 21 across the first and second trimester of pregnancy. Ann Clin Biochem 2002;39:567-576.
32. Spencer K, Crossley JA, Aitken DA, Nix AB, Dunstan FD, Williams K. The effect of temporal variation in biochemical markers of trisomy 21 across the first and second trimester of pregnancy on the estimation of individual patient specific risks and detection rates for Down's syndrome. Ann Clin Biochem 2003;40:219-231.
33. Lawrence JB, Oxvig C, Overgaard MT, Sottrup-Jensen L, Gleich GJ, Hays LG, Yates JR, Conover CA. The insulin-like growth factor (IGF)-dependent binding protein-4-protease secreted by human fibroblasts is pregnancy associated plasma protein-A. Proc Natl Acad Sci U S A 1999;96:3149-3153.
34. Spencer K, Crossley JA, Green K, Worthington DJ, Brownbill K, Aitken DA. Second trimester levels of pregnancy associated plasma protein-A in cases of trisomy 18. Prenat Diagn 1999;19:1127-1134.
35. Muller F, Sault C, Lemay C, Roussl-Mizon N, Forestier F, Frendo JL. Second trimester two step trisomy 18 screening using maternal serum markers. Prenat Diagn 2002;22:605-608.
36. Smith GS, Stenhouse EJ, Crossley JA, Aitken DA, Cameron AD, Connor JM. Early pregnancy levels of pregnancy associated plasma protein A and the risk of intrauterine growth restriction, premature birth, preeclampsia, and still-birth. J Clin Endocrinol Metab 2004;87:1762-1767.
37. Cowans NJ, Spencer K. First trimester ADAM12 and PAPPA as markers for intrauterine fetal growth restriction through their roles in the insulin-like growth factor system. Prenat Diagn 2007;27:264-271.
38. Lamson G, Giudice LC, Cohen P, Liu F, Gargosky S, Muller HL, Oh Y, Wilson KF, Hintz RL, Rosenfeld RG. Proteolysis of IGFBP-3 may be a common regulatory mechanism of IGF action in vivo. Growth Regul 1993;3:91-95.